Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02XUD
|
||||
| Former ID |
DNC010676
|
||||
| Drug Name |
4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H20N2O2
|
||||
| Canonical SMILES |
C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC(=C3)C4=CC=CC=C4
|
||||
| InChI |
1S/C20H20N2O2/c23-20-18(19(24-22-20)15-9-11-21-12-10-15)17-8-4-7-16(13-17)14-5-2-1-3-6-14/h1-8,13,15,21H,9-12H2,(H,22,23)
|
||||
| InChIKey |
KLKHVLINJXRNBG-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric acid receptor subunit alpha-1 | Target Info | Inhibitor | [1] | |
| Gamma-aminobutyric acid receptor subunit beta-2 | Target Info | Inhibitor | [1] | ||
| Gamma-aminobutyric acid receptor subunit gamma-2 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | |||||
| GABAergic synapse | |||||
| Morphine addiction | |||||
| Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| Nicotine addiction | |||||
| Reactome | Ligand-gated ion channel transport | ||||
| GABA A receptor activationR-HSA-975298:Ligand-gated ion channel transport | |||||
| GABA A receptor activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transportWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | J Med Chem. 2010 Apr 22;53(8):3417-21.Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relationships. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.